Please upgrade to Flash 8 or higher.
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity.
Orexigen has submitted an NDA with the FDA for its lead investigational product, Contrave® (naltrexone SR/bupropion SR). The Company's second product, Empatic™ (zonisamide SR/bupropion SR) has completed Phase 2 clinical development.
-
Product Candidates
Learn how our products go beyond the traditional approach to weight reduction.
-
Clinical Trials
Get up to date details of all our trials.
-
Our Technology
Discover what makes our technology and processes different.
-
Latest News
September 2, 2010 – Orexigen(R) Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave(R) in North America
